Enlicitide (Lipfendra): the oral macrocyclic peptide for cholesterol

What PCSK9 does, and why blocking it lowers cholesterol

LDL cholesterol is cleared from the blood mainly by LDL receptors on liver cells, which grab LDL particles and pull them inside. PCSK9 is a protein that binds those receptors and marks them for destruction, so the more PCSK9 there is, the fewer receptors survive and the higher blood LDL climbs. Block PCSK9 and the receptors recycle back to the cell surface, clearing more LDL.

That idea has been proven with injections. Two antibodies that block PCSK9 and a small interfering RNA that stops the liver making it are approved, and outcomes trials of the antibodies showed that lowering LDL this way cuts heart attacks and strokes when added to statins; Lipfendra's own label notes that such trials have shown reduced cardiovascular events with statins and with monoclonal antibody PCSK9 inhibitors ¹. The obstacle has always been delivery. PCSK9's binding surface is large and flat, the kind of target small-molecule pills rarely hit, which is why every PCSK9 drug until 2026 was injected.

The macrocycle: how a peptide became a pill

Enlicitide is a macrocyclic peptide, a chain of amino acids closed into a ring and braced with chemical cross-links. Rings resist the enzymes that chop linear peptides apart, hold a shape that can grip a flat protein surface, and can be tuned atom by atom. Merck's chemists describe building it from four fragments around the ring, plus a tail, so they could fix one problem at a time in an earlier lead compound: a sulphur atom that oxidised, poor solubility, an explosive azide group that made manufacture hazardous, and a double bond that formed mixtures of isomers. The result bound PCSK9 at low picomolar concentrations with better solubility, stability and pharmacokinetics ².

Making it at scale was a challenge of its own. A 2026 report in Science describes assembling enlicitide with a cascade of engineered enzymes that join peptide fragments and close the ring without protecting groups, cutting the number of synthesis steps by more than half compared with earlier methods ³. That matters because cost and supply decide whether a drug like this can reach the millions of people with high cholesterol.

Getting it absorbed: the role of sodium caprate

Even a well-engineered peptide is poorly absorbed from the gut. Each Lipfendra tablet contains sodium caprate, a fatty-acid salt that helps enlicitide cross the intestinal wall, and even so its oral bioavailability is about 1% ¹. That is the same strategy oral semaglutide uses with its own absorption enhancer, and a different one from icotrokinra, the oral psoriasis peptide approved in March 2026, which relies on extreme potency with no enhancer at all; our icotrokinra explainer compares the two approaches.

Low, enhancer-dependent absorption is why the label is precise. Lipfendra is taken once daily in the morning on an empty stomach, swallowed whole with water, black coffee or plain tea, and nothing else is eaten or drunk for at least 30 minutes; taken 30 minutes after a meal, exposure fell by about half (48% for total exposure and 50% for the peak) ¹. Black coffee and plain tea made no clinically meaningful difference ¹. These instructions are reproduced from the label for information, not as advice.

How the dose was chosen

The phase 2b trial gave 380 people one of four daily doses or placebo for eight weeks. LDL fell by 41.2%, 55.7%, 59.1% and 60.9% against placebo as the dose rose, with adverse events at rates similar to placebo ⁴. The curve flattens at the top, which is typical of drugs that saturate their target: going from the second-highest to the highest dose added under two points. The phase 3 programme then tested a single 20 mg daily dose, the dose on the label ^{5 1}. The label also notes that blood levels rise less than proportionally with dose across a wide range ¹, so a higher dose would not simply mean proportionally more drug in the blood.

What the trials showed

The trial programme, called CORALreef, tested enlicitide against placebo in a broad population and in familial hypercholesterolaemia, and against the other oral add-on drugs ^{4 5 6 7}:

The main trial enrolled 2,909 adults, average age 63 and 39% women, who had already had a heart attack, stroke or similar event with LDL of at least 55 mg/dL, or were at risk of a first event with LDL of at least 70 mg/dL; average LDL at the start was 96 mg/dL. Enlicitide also lowered non-HDL cholesterol, apolipoprotein B and lipoprotein(a), and adverse events did not appear to differ from placebo ⁵. A meta-analysis of the four randomised trials, 3,894 participants, put the average LDL reduction at about 56 percentage points, with reductions of about 48 points in apolipoprotein B and 23 points in lipoprotein(a) ⁸. Lipoprotein(a) matters because it is a largely inherited risk factor with no approved treatment of its own; a separate analysis found that the PCSK9-targeting drugs as a group lower it by about a quarter, without clear differences between them ⁹.

Who was studied, and who was not

The trials tell you who the evidence applies to. CORALreef Lipids enrolled adults who had already had a major atherosclerotic event, such as a heart attack or stroke, with LDL of at least 55 mg/dL, and adults at risk of a first event with LDL of at least 70 mg/dL; most were already on statins ⁵. The familial hypercholesterolaemia trial enrolled 303 adults with the inherited form, on background statins and, in 64.4%, ezetimibe as well ⁶. The head-to-head trial compared enlicitide with ezetimibe and bempedoic acid in 301 adults already taking statins ⁷.

Groups not covered by these trials include children, people with the much rarer homozygous form of familial hypercholesterolaemia, and pregnant or breastfeeding women; the approved indication is for adults ¹. And because the trials ran for one year at most, longer-term effects will come from the outcomes trial and from use after approval.

How it compares with injected PCSK9 drugs

No randomised trial has compared enlicitide directly with the injected PCSK9 antibodies or with inclisiran, so claims about which lowers LDL most rest on comparisons across separate trials with different patients. The size of the LDL reduction in CORALreef, about 56 points against placebo ⁵, is in the range people have come to expect from the injected class, and the meta-analysis found a similar picture across all four trials ⁸. What enlicitide does not yet have, and the antibodies do, is a completed outcomes trial showing fewer heart attacks and strokes ¹⁰.

For a patient, the practical comparison is one tablet every morning on an empty stomach against an injection every two weeks to six months, depending on the product. Some people will prefer a pill; others will find a twice-yearly injection easier to keep up than a daily routine that has to come before breakfast.

What the label says

FDA approved Lipfendra on July 15, 2026 as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia ^{11 1}. The dose is one 20 mg tablet daily, and the label says its effect on LDL can be measured as early as four weeks after starting ¹. Steady state is reached in about seven days. The drug is barely metabolised and is cleared mainly by the kidneys, about 73% of an intravenous dose appearing in urine; its effective half-life is about 14 hours, with a much longer terminal phase of about 244 hours ¹. As of October 3, 2026, it is not in the European Medicines Agency's register ¹¹.

The question still open: heart attacks and strokes

LDL is a validated surrogate: decades of trials show that lowering it with statins, ezetimibe and injected PCSK9 drugs prevents cardiovascular events in proportion to how far it falls. That is why regulators approve LDL-lowering drugs on LDL results. But a surrogate is not an outcome, and every new drug class has to show it does not carry hidden harms.

Enlicitide's outcomes trial, CORALreef Outcomes, has enrolled 14,550 participants and is active but no longer recruiting; its primary completion date, estimated, is November 29, 2029 ¹⁰. Until it reports, the claim that enlicitide prevents heart attacks rests on the class and on LDL, not on enlicitide itself. Its label says exactly that, citing outcomes trials of statins and the injected PCSK9 antibodies rather than of Lipfendra ¹.

Where it fits

For people whose LDL stays too high on a statin, the options have been ezetimibe or bempedoic acid tablets, which lower LDL modestly, or PCSK9 injections, which lower it a lot. Enlicitide offers the size of effect of the injections in a daily pill: in a direct comparison it lowered LDL far more than either oral add-on, or both together ⁷. The trade-offs are the strict morning routine, one tablet every day rather than an injection every two weeks to six months, and the outcomes data still to come. Cost and coverage, not yet settled, will matter as much as the trial results.

Enlicitide's broader significance, alongside icotrokinra, is that engineered peptides can now reach targets once reserved for injected antibodies; our 2026 pipeline overview puts both in context. None of that engineering carries over to research peptides sold online, which are not made, tested or absorbed like an approved tablet.

Frequently asked questions

What is Lipfendra?

Lipfendra is the brand name for enlicitide, a once-daily oral peptide that blocks PCSK9 to lower LDL cholesterol. FDA approved it on July 15, 2026 for adults with high LDL cholesterol, including familial hypercholesterolaemia.

How much does enlicitide lower cholesterol?

In the main phase 3 trial, LDL cholesterol fell 57.1% on enlicitide against a 3.0% rise on placebo at 24 weeks, a difference of about 56 percentage points.

Does enlicitide prevent heart attacks?

That has not yet been shown for enlicitide itself. Its outcomes trial, CORALreef Outcomes, has 14,550 participants and is expected to reach primary completion in late 2029.

How do you take Lipfendra?

The label says one 20 mg tablet in the morning on an empty stomach, swallowed whole with water, black coffee or plain tea, waiting at least 30 minutes before other food or drink.

Related on Grey Peptides

• Enlicitide
• Peptide pipeline tracker
• Icotrokinra (Icotyde)

Sources

1. Merck Sharp & Dohme. Lipfendra (enlicitide decanoate) tablets, US prescribing information, sections 1, 2 and 12.3 (DailyMed version 2, effective July 15, 2026). Read October 3, 2026.
2. Josien, H., et al. (2026). Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. J Med Chem, 69(11), 13473-13491. PMID: 42201324
3. Klapars, A., et al. (2026). Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide. Science, 392(6798), 643-647. PMID: 42096573
4. Ballantyne, C. M., et al. (2023). Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol, 81(16), 1553-1564. PMID: 36889610
5. Navar, A. M., et al. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med, 394(6), 529-539. PMID: 41879224
6. Ballantyne, C. M., et al. (2026). Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA, 335(2), 129-139. PMID: 41206969
7. Catapano, A. L., et al. (2026). Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol, 88(3), 340-352. PMID: 42017875
8. Yagmur, B., et al. (2026). Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis, 13(8). PMID: 42645869
9. Mulligan, M. D., et al. (2026). Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials. J Clin Lipidol, 20(6), 1054-1064. PMID: 42025558
10. ClinicalTrials.gov. NCT06008756: Enlicitide decanoate (MK-0616) cardiovascular outcomes study (CORALreef Outcomes), phase 3, 14,550 participants, active not recruiting, primary completion estimated November 29, 2029. Read October 3, 2026. ClinicalTrials.gov
11. Grey Peptides encyclopedia entry for enlicitide: approval details (Drugs@FDA NDA 220848; EMA register read September 30, 2026). Read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.